Drug 42756493BLC2003: A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) and FGFR Mutations or Fusions
The purpose of this study is to see if erdafitinibis safe and useful for treating patients with high risk non-muscle invasivebladder cancer (NMIBC) that recurred (came back) after BCG therapy and has agene mutation or fusion called FGFR.
1) Histologically confirmed, recurrent, non-muscle invasive urothelial carcinoma of the bladder
2) Age of at least 18 years
3) There are other tests required to confirm if you are eligible. All prospective patient will undergo these tests to determine if they are eligible to take part in the study.
Note: This is only a partial list of eligibility criteria. Pleasecontact the Robert H. Lurie Comprehensive Cancer Center of NorthwesternUniversity for complete screening information if you are interested in thisclinical trial.